Abstract Purpose: The poor survival rate of hepatocellular carcinoma (HCC) is in part due to the inability to diagnose patients at an early stage. Therefore, the aim of this study was to search for candidate serum marker for HCC and to test their ability to distinguish a HCC from benign liver disease. Experimental Design: Genome-wide analysis by a microarray in 40 HCC patients was done between HCC and paired nontumor liver tissues. Expression of cystatin B (CSTB) was examined by mRNA expression analysis and immunohistochemistry.The serum CSTB levels were measured using a sandwich ELISA method in four groups, including normal healthy subjects (group 1, n = 52) and patients with noncirrhotic chronic hepatitis (group 2, n = 53), cirrhosis (group 3, n = 43), and HCC (group 4, n = 62). Results: Microarray and statistical analyses identified 248 genes that were expressed differently between HCC and nontumor liver tissues. One of them, CSTB, was expressed preferentially in the HCCs compared with the nontumor tissues, 36 of 45 specimens (80%) by Northern blot and semiquantitative reverse transcription-PCR analyses. The serum CSTB level was much higher in HCC patients than in those with nonmalignant chronic liver disease (groups 2 and 3; P < 0.0001).
The receiver operating characteristic curve indicated 5.34 ng/mL to be the optimal value for CSTB, and the sensitivity and specificity for this CSTB value were 85.5% (95% confidence interval, 74.2-93.1%) and 53.1% (95% confidence interval, 42.7-63.4%), respectively, in distinguishing between patients with HCC and those with nonmalignant chronic liver disease. Conclusion: CSTB is specifically overexpressed in most HCCs and is also elevated in the serum of a large proportion of HCC patients. CSTB or the combination of CSTB and a-fetoprotein may be a useful marker for diagnosing patients with HCC with a high sensitivity.
Hepatocellular carcinoma (HCC) ranks fifth in frequency among all malignancies worldwide and causes f1 million deaths annually (1, 2) . It has a heterogeneous geographic distribution, with its greatest incidence in Asia and sub-Saharan Africa, where hepatitis B is endemic (3) . Its incidence has also been increasing steadily in the United States and Western Europe due to the high prevalence of chronic hepatitis C (4).
Cirrhosis, regardless of its etiology, is the dominant risk factor for HCC and exposure to aflatoxin, alcohol, and/or iron overload is also associated with development of HCC (3). The 5-year survival of HCC has not improved significantly over the last 2 decades, from 2% to 5%. This poor survival rate is in part related to HCC being generally diagnosed at an advanced stage where effective therapies are lacking (5) . The surveillance of patients at the highest risk of developing HCC is an important strategy that can potentially decrease the cancer-related mortality rate. The lack of molecular markers that can characterize tumor formation and tumor progression precludes making an effective diagnosis and monitoring prognosis of HCC. Although a diagnosis of HCC currently relies on the presence of a liver mass on the radiology imaging studies, the detection of an elevated serum a-fetoprotein (AFP) level is still a widely used serum marker for diagnosing and monitoring HCC (6, 7) . However, the AFP levels have low sensitivity and specificity (i.e., it is normal in up to 40% of patients with a HCC), particularly during the early stages (low sensitivity), and elevated in patients with cirrhosis or exacerbations of chronic hepatitis (low specificity; refs. 8, 9) . Several biomarkers, such as des-g-carboxyprothrombin/prothrombin induced by vitamin K absence-II, lens cularis agglutinin-reactive (AFP-L3), and glypican-3, have been examined for their ability to detect early HCC (10) . Therefore, there is a need for additional serum markers that will improve the detection rate of early HCC.
Cystatins are endogenous inhibitors of lysosomal cysteine proteinases, such as cathepsin L, H, and S (11) . Cystatin B (CSTB) is a member of the cyctatin superfamily and mutations resulting in a loss of function are responsible for UnverrichtLundborg myoclonus epilepsy (EPM1), which is an inherited, progressive, and lethal autosomal disease (12, 13) . Furthermore, the activity of CSTB has been reported in several human carcinomas, such as human colorectal carcinoma and gastric cancer (14, 15) , whereas a lower CSTB expression level was observed in esophageal carcinoma and prostatic adenocarcinoma (16, 17) . There is little information on CSTB expression along with its implications in various cancers. The recent developments of gene expression microarrays and proteomics have allowed thousands of genes and proteins to be screened simultaneously, which will lead to the development and evaluation of these biological markers. Genome-wide analysis by a microarray was used to obtain comprehensive information about the transcription profile of HCC. The results showed that CSTB mRNA is overexpressed preferentially in HCC. Hence, the present study examined whether the CSTB protein level is immunohistochemically detectable in tumor tissues in HCC, compared with the corresponding nontumor tissues, and assayed whether CSTB level is significantly elevated in the serum of HCC patients compared with patients with a normal liver or chronic liver disease.
Materials and Methods
Patient tissues. For tissue microarray technology, 40 surgically resected HCC and their matched nontumor tissues were studied. The Research Ethics Committee of Chonbuk National University Hospital approved the study. All 40 patients had HCC and underwent a curative liver resection. Paired samples of tumor and corresponding cirrhotic nontumor tissue were obtained from the resected liver specimen. Written informed consent was obtained from each patient. Pathologists histologically confirmed HCC and nontumor tissues. After the resection, the tissues were rinsed in sterile PBS and immediately snap frozen and stored in liquid nitrogen until used for RNA isolation. The total cellular RNA was extracted using a Trizole kit (MRC). The integrity of the RNA specimen was verified by gel electrophoresis. In addition, the tissues were derived from surgical resections and had been rapidly fixed in 10% buffered formalin and embedded in paraffin for the standard histopathology analysis. This protocol conformed to the ethical guidelines of the Institutional Review Board.
Microarray hybridization, data collection, and analysis. Preparation of fluorescence-labeled cDNA and microarray hybridization of cDNA microarrays (10K) were used in this study and made by the 21C Frontier (The Center for Functional Analysis of Human Genome, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea). The microarray slides collectively contained a total of 3,286 unique sequence-verified clones and housekeeping genes. Hybridization was done as previously described (18) . The human reference RNA, which contained the total RNA samples from six different normal livers, was used as a reference for cDNA microarray analysis. The purified and concentrated fluorescence-labeled cDNA from the reference and experimental samples was processed. The signals from each immobilized cDNA target on a microarray slide were localized, and the expression ratio between the experimental and reference samples (Cy5/ Cy3 ratio) was determined using ImaGene 5.2 (BioDiscovery). The correlation between the intensity value for each cDNA and the HCC and reference tissues was examined using scatter plots, and a linear relationship was obtained in log space. All the ImaGene files were uploaded into the Liver cancer database 5 of the Korean BioInformation Center. 6 All spots with signal intensities <50% of those of the local background were flagged and eliminated. The data were normalized using the print tip loess normalization with the limma in R packages 7 on Bioconductor. 8 Genes with expression values >80% of the entire tissues were retained for further analysis. A hierarchical clustering algorithm was used in all tissues and genes using the Pearson uncentered correlation coefficient as a similarity measure and complete linkage clustering in TIGR MultiExperiment Viewer (version 3.11) software (19) . A two-sample t test based on 10,000 random permutations in the R packages was used to statistically analyze the differentially expressed genes. The q value package in Bioconductor was used to calculate the q values as a measure of the significance of the genes. Genes with a q value of <0.05 and a mean difference between the two groups of >1.5 were selected.
Patient sera. Demographic and clinical information was collected from each subject. Four groups of consecutive subjects were enrolled. Group 1 (G1; n = 56) included normal healthy subjects with no history of liver disease. All subjects had a normal liver biochemistry. Group 2 (G2; n = 52) consisted of patients with histologically confirmed noncirrhotic chronic hepatitis. Group 3 (G3; n = 43) included patients with histologically proven cirrhosis with compensated or decompensated liver disease. Group 4 (G4; n = 62) consisted of independent patients with histologically or radiologically proven HCC, whose resected tissues were not used in the microarray, Northern blot, and reverse transcription-PCR (RT-PCR) analyses. The etiology of the underlying liver disease was attributed to hepatitis B virus based on hepatitis B surface antigen in serum, hepatitis C virus based on the detection of hepatitis C antibody/hepatitis virus RNA in serum, and alcohol based on a daily alcohol intake of >40 g/d ethanol for >15 years. The etiology of liver disease was considered to be cryptogenic if there was no identifiable cause. The serum was immediately separated by centrifugation and frozen at -20jC. HCC was diagnosed histologically when the surgical liver specimens were available. Sera were collected from the patients who belong to each group.
Cell lines and transfection. HCC cell lines, including HepG2, Hep3B, PLC/PRF/5, Huh7, and SK-HEP-1 cells, and immortalized epithelial cell lines, such as THLE-3 and 293T cell, were obtained from the American Type Culture Collection. HKL2, HKL3, HKK2, HKK2, and HKL6 cells were established from the surgical specimens from the HCC patients in our laboratory. The cells, except for THLE-3, were maintained at 37jC in a humidified atmosphere containing 5% CO 2 and cultured in MEM with 10% fetal bovine serum (Life Technologies) supplemented with MEM and sodium pyruvate (1 mmol/L). The THLE-3 cells were cultured in a BEGM bullet kit (Clonetics). The Hep3B and 293T cells were transfected with a green fluorescent protein (GFP)-tagged CSTB cDNA introduced into pEGFPN3 vector (BD Biosciences) or myc-tagged CSTB cDNA introduced into pcDNA3.1/MycHis vector (BD Biosciences) or the empty vector as a control.
Northern blot analysis and RT-PCR. Samples containing 20 Ag of the total nontumor or tumor RNAs were fractionated on 1% agarose gels containing 2.2% formaldehyde and 50 mmol/L MOPS and transferred to a nylon membrane. The membrane was cross-linked using as UV cross-linker (Stratagene) and individually hybridized with the CSTB cDNA probe labeled with [a-
32 P]dCTP (3,000 Ci/mmol; NEN Life Science Products) by random priming. The hybridization and washing conditions were the same as those described previously (20) , and the blots were then exposed to X-ray film at -70jC. To confirm the amounts of mRNA loaded in each lane, the blots were hybridized afterwards with an 18S cDNA probe. Alternatively, reverse transcription was done using 10 Ag total RNA, 50 Amol/L decamer, and 1 AL (200 units) RT-PCR SuperScript II (Invitrogen) at 37jC for 50 min. PCR amplification was then done in a 20 AL reaction mixture containing 1 AL of each diluted reverse transcriptase product and 100 pmol of each primer for CSTB. The PCR conditions were 94jC for 1 min, 65jC for 1 min, and 72jC for 35 cycles. The QuantumRNA 18S Internal Standard kit (Ambion) was used as the internal control according to the manufacturer's instruction. The primer sequences for CSTB were 5 ¶-GTCGCCGCCAAGATGATG-TGC-3 ¶ (sense) and 5 ¶-GAAATAGGTCAGCTCATCATG-3 ¶ (antisense). The PCR products were separated by electrophoresis on 2% agarose gel and visualized under UV light after ethidium bromide staining. 18S was used as the internal control.
Immunohistochemistry and immunofluorescence. Immunohistochemical staining was done on formalin-fixed, paraffin-embedded, 4-Am-thick tissue sections. After rehydration, a deparaffinized section was pretreated by microwave epitope retrieval [750 W during 15 min in 10 mmol citrate buffer (pH 6.0)]. Before applying the primary antibody, the endogenous peroxidase activity was inhibited with 3% hydrogen peroxide, and a biotin with bovine albumin blocking step was done. The primary mouse monoclonal antibody (mAb) for CSTB (RJMW2E7, Alexis Biochemicals) and newly optimized in-house rabbit polyclonal antibody (PMA06) were detected using a secondary biotinylated antibody and a streptavidin-horseradish peroxidase conjugate according to the manufacturer's instructions (DAKO). Polyclonal PMA06 antibody to CSTB was affinity purified from the sera of an immunized rabbit with the recombinant glutathione S-transferase-CSTB protein produced by Escherichia coli. Counterstaining was done using Meyer's hematoxylin. The tumors were evaluated for the percentage of positive cells and the intensity of staining. The negative controls included samples incubated with PBS or with mouse IgG1 instead of the primary antibody. For immunofluorescence, the cells were grown and transfected with GFP-tagged CSTB expression vector or empty vector control on glass coverslips, fixed with 4% paraformaldehyde, permeabilized in PBS containing 0.2% Triton, and Research.
on April 13, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from blocked with 1% bovine serum albumin. The cells were incubated with mouse monoclonal CSTB antibody overnight at 4jC, washed, and incubated with tetramethylrhodamine isothiocyanate isomer R -conjugated swine anti-mouse immunoglobulin. After a final wash, the cells were stained with 1 Ag/mL Hoechst 33258 for 15 min to visualize the nuclei and mounted with 50% glycerol in PBS at 4jC. The cells were examined using a laser scanning microscope (LCM 510, Carl Zeiss). CSTB ELISA. The serum level of CSTB was determined using human stefin B ELISA test kit (KRKA d.d.). For CSTB ELISA, murine A6/2 mAb was used for the capture, and murine E7/1 mAb, conjugated with horseradish peroxidase, was used for detection (21, 22) . Sera in a 1:2 dilution were used in the assay. The detection limit of the assay was 0.6 ng/mL. To quantify the CSTB present in the serum, a calibration curve of recombinant human CSTB added to the serum at the same dilution as a pool of normal sera was done in parallel. A microplate reader (Molecular Devices Co.) was used to measure the absorbance in ELISAs. The CSTB levels are expressed in ng/mL of serum and were measured twice in duplicate.
Immunoblotting. The extracted protein (30 Ag) from the cell lysates was resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The membranes were incubated for 1 h at room temperature in a primary CSTB antibody (at 1:2,000 dilution). Two types of the primary CSTB antibody, RJMW2E7 and PMA06, were used. After incubation, the blots were washed thrice in PBS/0.1% Tween 20. The immunoreactive CSTB was then detected using alkaline phosphatase -conjugated goat anti-rabbit IgG or using a commercial chemiluminescence detection kit (Amersham) according to the manufacturer's instructions. To collect the conditioned medium, the cell lines were grown to a high density overnight in the absence of serum. The collected medium was concentrated using Centricon YM100 filters (Millipore). Protein (20 Ag) was used for immunoblotting. For serum immunoblotting, 10 AL diluted serum (1:1) with 1% bovine serum albumin was resolved by SDS-PAGE and transferred to a nitrocellulose membrane.
Quantification and statistical analysis. Autoradiographs of Northern hybridizations were scanned using the LAS3000 system (Fuji Photo Film), and the densitometric data were analyzed. The expression levels of each tumor tissue relative to the nontumor tissue were calculated after normalizing the results to the level of 18S. Differences in the levels of CSTB between the groups were tested by either a Mann-Whitney test or unpaired t test. A P value of <0.05 was considered significant. The optimal cutoff value for CSTB and AFP in the diagnosis of HCC was determined by receiver operating characteristic (ROC) curve analysis using MedCalc or Statistical Package for the Social Sciences 15.0 software. The best cutoff values for CSTB and AFP were chosen automatically with the highest diagnostic accuracy (i.e., the sum of the false-negative and false-positive rates was minimized). The respective overall diagnostic values are expressed using the area under the ROC curve (AUC; refs. 23, 24) . The logistic regression model was applied to the data to combine the markers (24, 25) .
Results

CSTB2 gene expression in HCC.
The gene expression patterns of the primary HCC tumor specimens and corresponding nontumor liver tissue specimens from the 40 patients were examined using a cDNA microarray. The genes were chosen based on them being present in at least 80% of HCCs and nontumor tissues. Hierarchical clustering analysis was based on all the tissues according to the similarity in expression pattern of all genes (Fig. 1A, left) . All tissues were completely separated into two main groups, nontumor liver tissues and tumor tissues, except for one nontumor tissue that belonged to a major HCC cluster. In two major clusters, the genes that distinguished between the HCC and nontumor liver tissues under the condition of false discovery rate (<1%) were identified. Of the 248 genes, 149 genes were expressed more preferentially in the HCCs than in the nontumor tissues. Table 1 lists the top 20 genes differentially expressed between HCCs and the matched nontumor tissues. Among them, this study focused on the preferential expression of CSTB in HCC because up-regulated genes encoding secreted proteins are of particular interest for their potential diagnostic value. CSTB was expressed preferentially in the HCC cluster compared with the nontumor cluster (Fig. 1A, right) . Validation by Northern blot and semiquantitative RT-PCR analyses showed that CSTB mRNAs were expressed preferentially in 45 HCCs, which included 30 independent samples not used in the microarray analysis, compared with the corresponding nontumor tissues (80%, 36 of 45; Fig. 1B) .
Detection of CSTB by immunoblot, immunofluorescence, and immunohistochemistry. To determine the specific immunoreactivity of CSTB by the mouse mAb RJMW2E7 or the rabbit polyclonal antibody PMA06, 293T cells were transfected with GFP-or myc-tagged CSTB expression vector and RJMW2E7 Research.
on April 13, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from mAb or PMA06B antibody reactivity was assayed by immunoblot analysis. Because the transfected CSTB cDNA contained a GFP tag or a myc tag in the COOH terminus, an immunoblot was also done on the same membrane using an anti-GFP rabbit polyclonal antibody (FL, Santa Cruz Biotechnology) or an antic-Myc mouse mAb (9E10, Santa Cruz Biotechnology). The RJMW2E7 antibody or PMA06B antibody specifically detected the band corresponding to the CSTB protein ( Fig. 2A) . On the other hand, Hep3B and 293T cells were transfected with the GFP-tagged CSTB expression vector or empty vector, and RJMW2E7 mAb or the PMA06B antibody reactivity was assayed by immunofluorescence (Fig. 2B) . The comparison between the fluorescence and transmission images showed that the ectopic expression of GFP-tagged CSTB is located in both the nucleus and the cytoplasm of both cells analyzed, which is consistent with a previous report (26) . The green fluorescence perfectly overlapped with the CSTB immunoreactivity. However, the endogenous CSTB expression detected by RJMW2E7 mAb was mainly localized in the cytoplasm of the cells. Next, CSTB expression was examined in paraffin-embedded tissue sections from HCC and nonmalignant liver disorders using RJMW2E7 mAb or the PMA06 antibody. CSTB was expressed preferentially in HCC (Fig. 3B ) compared with that in the corresponding nontumor liver tissues. Positive immunoreactivity for CSTB was observed in the cytoplasm of most HCC cells and less frequently in the nuclear and cytoplasm in the front marginal tumor cells (Fig. 3C) . However, CSTB immunoreactivity was detected mainly in the nuclei in the invasive tumor cells (Fig. 3D ). This suggests that CSTB expression may participate in tumor invasion to the surrounding tissue.
Secreted CSTB in HCC cell lines and serum samples. The secreted CSTB was analyzed in serum-free conditioned medium of immortalized liver cells (THLE-3) and hepatoma cell lines, including HepG2, Hep3B, PLC/PRF/5, Huh7, SK-HEP-1, SH-J1, HKL2, HLK3, HKK2, and HKL6. Western blot analysis showed that hepatoma cells obviously secrete the CSTB protein in the conditioned medium and that the amount of secreted CSTB was higher in the HepG2, PLC/PRF/5, Huh7, SK-HEP-1, SH-J1, and HLK6 cells than in the THLE-3, Hep3B, HKL2, HLK3, and HKK2 cells (Fig. 4A) . The expression of the CSTB protein was examined in the cell lysates of the Hep3B cells stably transfected with the expression vector pcDNA3.1/Myc-HisA. The stable transfectant CSTB11, CSTB17, CSTB18, and CSTB28 cells substantially expressed CSTB compared with the vector control VC2 and VC4 cells (Fig. 4B) . The secreted CSTB in the serum among normal subjects, the patients with nonmalignant liver disease (chronic hepatitis and liver cirrhosis), and the patients with HCC was also compared. The CSTB levels in the HCC patients were significantly higher than those of the normal subjects or nonmalignant liver disease (Fig. 4C) .
Serum levels of CSTB. In relation to the profiles in tumor tissues, the serum level of CSTB reflected not only the changes in their local expression in tumors and in protein secretion but also the systemic response to cancer (22) . Therefore, a sandwich ELISA was used and the serum levels of CSTB (Fig. 5A) and AFP (Fig. 5B) were measured in 52 subjects in G1, 53 in G2, 43 in G3, and 62 in G4 ( Table 2 ). The patients' age increased from G2 to G4 with a mean of 43.7 F 11.8 (mean F SD), 54.1 F 10.1, and 59.1 F 10.4 (P < 0.016), which suggests that HCC develops in the late stage of nonmalignant chronic liver disease. There was no significant difference in the model for end-stage liver disease score (12.8 F 5.3 versus 12.4 F 6.3) between G3 and G4. It was found that the serum levels of CSTB increased from G2 to G4 with median (range) levels of 3.3 (0.8-23.4), 7.8 (0.7-27.0), and 10.8 (1.6-142.5) ng/mL (P < 0.0001). There was no significant difference in the serum CSTB levels between the subjects in G1 and G2 (P = 0.8325). The subjects in G3 and G4 showed significantly elevated CSTB levels (P = 0.0128 and P < 0.0001, respectively) compared with the subjects in G2. Furthermore, the subjects in G4 revealed much higher serum CSTB levels than the subjects in G3 (P = 0.0038). Importantly, the serum CSTB levels in HCC were significantly higher than in those with nonmalignant chronic liver disease, including G2 and G3 (P < 0.0001). The median (range) AFP levels were 4.9 Fig. 3 . Immunohistochemical detection of CSTB in HCC and nontumor liver tissues using the anti-CSTB RJMW2E7 mAb. A, CSTB-negative hepatocytes, blood vessels, and bile ducts in the normal liver area. B, overview of a CSTB-positive HCC surrounded by CSTB-negative nontumor liver area, including hepatocytes, fibrous capsule, and infiltrative blood cells. Inset, mainly cytoplasmic staining for CSTB in malignant hepatocytes. C, in addition to diffuse cytoplasmic staining for CSTB in most HCC cells, nuclear and cytoplasmic staining in the malignant hepatocytes in the marginal front. D, strong nuclear and cytoplasmic staining for CSTB in the invasive HCC cells. Original magnifications, Â100 (A and B) and Â200 (C and D).
( 1.3-165.0), 5.5 (1.1-399.6) , and 47.1 (2.0-75195) ng/mL for G2, G3, and G4, respectively. In contrast to the serum CSTB levels, there was significant difference in the serum AFP levels between the subjects in G1 and G2 (P < 0.0001), which might be due to elevated AFP levels in the subjects in G2. The subjects in G4 showed significantly elevated serum AFP levels compared with the subjects in G2 (P < 0.0001) but the subjects in G3 did not (P = 0.1799). The subjects in G4 also showed much higher serum AFP levels than the subjects in G3 (P < 0.0001). The serum AFP levels in the HCC patients were also significantly higher than those in the nonmalignant chronic liver disease, including G2 and G3 (P < 0.0001).
Cutoff values for CSTB and AFP in differentiating HCC from nonmalignant chronic liver diseases. The ROC curves were plotted to identify a cutoff value that would best distinguish HCC (G4) from nonmalignant chronic liver disease (G2 and G3; Fig. 6A ). The optimal values for CSTB and AFP were 5.34 and 11.3 ng/mL, respectively. These values yielded a sensitivity and specificity for CSTB of 85.5% [95% confidence interval (95% CI), 74.2-93.1%] and 53.1% (95% CI, 42.7-63.4%) and for AFP of 72.6% (95% CI, 59.8-83.1%) and 76.0% (95% CI, 66.2-84.2%), respectively. The positive and negative predictive value was 54.1 and 85.0 for CSTB and 66.2 and 81.1 for AFP, respectively. The AUC curve indicated no significant difference in sensitivity and specificity between CSTB and AFP for differentiating HCC from nonmalignant chronic liver disease (0.746 versus 0.802; P = 0.262). This suggests that the optimal value for CSTB showed a higher sensitivity and a lower specificity than AFP. To determine if a combination of CSTB and AFP was better than either of these markers by itself, a new variable combining CSTB and AFP was created using a logistic regression model, that is, logit(P HCC ) = ln[P HCC / (1 -P HCC )]. This combination had a sensitivity, specificity, and AUC of 72.6% (95% CI, 59.8-83.1%), 78.1% (95% CI, 68.5-85.9%), and 0.824, respectively (Fig. 6B) . The AUC indicated a better sensitivity and specificity for the combination of CSTB and AFP for differentiating HCC from nonmalignant chronic liver disease than with CSTB alone (0.824 versus 0.746; P = 0.008). However, this combination produced similar results to AFP alone (0.824 versus 0.802; P = 0.535). Therefore, these two markers seemed to be partly correlated.
The sensitivity of HCC with higher serum CSTB levels than the optimal value (positive CSTB) was compared with that of positive AFP to determine potential usefulness of CSTB to detect early HCC according to tumor size. Positive CSTB was found in 73.3% of HCCs that measured V3 cm in diameter and in 89.4% of the larger tumors (Table 3 ). In contrast, positive AFP was found in 80% and 70.2%, respectively. CSTB had a higher sensitivity in discriminating the large HCC from nonmalignant liver disease. However, there was no statistical significance observed in detecting small HCC (P = 0.6547).
Discussion
Among the top 20 genes expressed preferentially in HCC, 3 candidate genes (SPARC, CSTB, and AGC1) encode known serum proteins and may serve as potential diagnostic biomarkers. SPARC is related to HCC angiogenesis and tumor progression (27) . AGC1 is the major proteoglycan of the cartilage extracellular matrix and seems to be involved in the fibrogenic process in rat (28) . The serum levels of the cysteine proteinase inhibitor cystatins as well as lysosomal proteases cathepsins have been reported to be higher in patients with various types of tumors (29, 30) . However, the levels of CSTB in HCC have not been determined yet. Therefore, this study examined the CSTB level in serum to determine its value as a potential marker for HCC in comparison with AFP. In addition, another 140 samples (100 HCC and 40 nontumor) were further analyzed using Illumina bead arrays (Sentrix Human-6 Expression BeadChip v2.0, Illumina) containing the probes for 48,000 transcript probes to provide sufficient statistical power to the class comparison analyses. It was also found that CSTB is expressed preferentially in HCC (mean fold change, 1.9; q value = 0). Northern blot and RT-PCR analyses confirmed that CSTB mRNA is overexpressed in up to 80% of HCCs in the independent samples, which is similar to the microarray data. In this study, it was found that CSTB is more sensitive in differentiating patients with HCC from those with nonmalignant chronic liver disease but less specific than AFP, although the difference between the CSTB and AFP AUC was not significant (0.746 versus 0.802; P = 0.262). Moreover, a combination of CSTB and AFP was more specific than CSTB alone (0.824 versus 0.746; P = 0.008).
The cystatin superfamily can be divided into three families. The first includes the acid and neutral cysteine proteinase inhibitors cystatin A and CSTB, both of which are intracellular 12 kDa proteins with no disulfide bonds or carbohydrate groups. The second family includes cystatins C, D, E/M, F, S, SA, and SN, which are 13 kDa secretory proteins with two disulfide bonds in their COOH terminus. In contrast to the other cysteine proteinase inhibitors, CSTB harbors a free cysteine residue in the NH 2 -terminal part of the proteinase-binding domain (31) . CSTB is a 98 -amino acid protein that binds tightly to cathepsins B, H, and L and is expressed in the cells with a monocyte-macrophage lineage. CSTB inhibits lysosomal cathepsin, and the intracellular distribution of CSTB is dependent on the differentiation status of the cells (32) . Indeed, CSTB is found mainly in the nucleus of proliferating cells or in both the nucleus and the cytoplasm of differentiated cells (26) . However, these results suggest that endogenous CSTB is localized in the cytoplasm, whereas ectopic CSTB is localized in both the nucleus and cytoplasm of Hep3B or 293T cells. A trace amount of CSTB as well as cystatin A can be found in normal human serum as well as other biological fluids (33) .
The extracellular levels of stefins and cystatin C are associated with cancer progression. A study of the sera from colorectal cancer patients revealed a correlation between the CSTB levels and the Dukes' stage, its level being the highest in stage D (22) . However, the cystatin A serum levels were significantly higher in liver cirrhosis patients than in the HCC patients. The cystatin A serum levels correlated with the tumor size, number of neoplastic lesions, and serum AFP level in HCC patients (29) . This study found that the serum CSTB levels seemed to increase according to the stepwise progression of liver disease (i.e., from chronic hepatitis to HCC). However, the difference in the CSTB levels was not significant between the patients with noncirrhotic chronic hepatitis and normal healthy subjects. In contrast, the serum AFP levels were significantly higher in the patients with noncirrhotic chronic hepatitis than in the normal healthy subjects. This suggests that the serum CSTB levels are modulated by the existence of liver cirrhosis and the development of HCC. The ROC curve showed that the optimal Fig. 5 . Serum concentration of CSTB (A) and AFP (B) in the normal healthy subjects (G1) and in patients with noncirrhotic chronic hepatitis (G2), cirrhosis (G3), and HCC (G4). The serum levels of CSTB were examined by ELISA. Box-and-whisker plot for the CSTB and AFP values in the four groups of subjects. The box indicates the 25th and 75th percentile of the data and the middle line indicates the median. A vertical line extends from the minimum to the maximum value, excluding the outside and far-out values, which are displayed as separate points. Significance of the differences between the average values for the various patient groups was determined using a Mann-Whitney test, and the P values are shown. Table 2 . Demographic information and etiology of liver disease G1 (n =52) G2 (n = 53) G3 (n = 43) G4 (n = 62) P cutoff CSTB value for differentiating HCC patients from those with nonmalignant chronic liver diseases was 5.34 ng/mL, which indicates a higher sensitivity than the optimal cutoff AFP value of 11.3 ng/mL (85.5% versus 72.6%). The sensitivity and specificity of AFP for HCC are strongly dependent on the cutoff value above which AFP is considered positive. A recent report showed that the optimal cutoff AFP value for a diagnosis of HCC was 11 ng/mL (24) . At this level, the sensitivity and specificity was 77% and 73%, respectively. On the other hand, another recent study reported that the optimal cutoff AFP value for a diagnosis of HCC was 30 ng/mL (34) . This cutoff value was found to be more useful in detecting nonviral HCC because the positive predictive value was significantly higher than in viral HCC (94% versus 70%). This confirms the limited value of AFP in diagnosing HCC with a viral etiology. In contrast, the majority (71%) of subjects in this study had a hepatitis B virus origin. This suggests that the cutoff value for AFP might differ according to the ethnicity or etiology. For example, AFP was less sensitive for diagnosing hepatitis C virus -related HCC in African-Americans than in Caucasians (35) . Several studies found that a combination of des-g-carboxyprothrombin and AFP was more sensitive and specific for diagnosing HCC than with either marker alone (36, 37) . On the other hand, another study showed that this combination was not significantly better than either one alone (24) . Nevertheless, this study found that a combination of CSTB and AFP was significantly better than CSTB alone but not AFP alone. This is believed to be due to the lack of a significant difference between the CSTB and AFP AUC. The present data showed that the sensitivity of CSTB is higher than that of AFP in tumors >3 cm in diameter. The mean serum level of CSTB was 10.9 ng/mL (F1.9) in patients with a HCC V3 cm in size and 19.9 ng/mL (F3.8) in those with a HCC >3 cm. The larger tumors had a higher serum CSTB than the smaller tumors (P = 0.0346). In this study, the sample size was limited to detecting only a difference between malignant and nonmalignant chronic liver diseases, not a difference between the tumor stages. Thirty-eight patients did not undergo a surgical resection of the HCC because of a huge or multiple tumor masses with vascular invasion or with a poor functional reserve of the liver, whereas 24 patients underwent surgery. Interestingly, the mean serum level of CSTB (22.9 ng/mL) in the inoperable patients was significantly (P = 0.026) higher Fig. 6 . ROC curves comparing CSTB, AFP, and a combination of CSTB and AFB in patients with HCC (G4) versus those with noncirrhotic chronic hepatitis (G2) and cirrhosis (G3). A, the curves show the optimal cutoff value for CSTB of 5.34 ng/mL and for AFP of 11.3 ng/mL. B, the AUC curves for CSTB, AFP, and the combination and a pairwise comparison of the AUC between the combination and either CSTB or AFP are indicated. (9. 63 ng/mL) than in the operable patients. This suggests that the serum level of CSTB might also be due to an intrahepatic metastasis or vascular invasion. Moreover, a positive immunoreactivity for CSTB was observed in the cytoplasm of most HCC cells. However, strong immunoreactivity was detected mainly in the nuclei of invasive tumor cells. Accordingly, it was reported that an imbalance between cathepsins and cystatins, which is associated with the metastatic tumor cell phenotype, facilitates tumor cell invasion and metastasis (38) .
Patients with cirrhosis are an ideal target population for HCC surveillance (39) . Therefore, a prospective study of patients with cirrhosis will be needed to further validate the utility of CSTB as a marker for the detection of early HCC. The important question is whether CSTB is a better or complementary marker for detecting early HCC than AFP. In addition, a cross-sectional study should be designed to address this question. Furthermore, because it is possible that a combination of two or three markers will increase the sensitivity achieved with a single marker, a combined score of CSTB and AFP might prove useful in the clinical setting and will be subject of future studies. Additional data will also be needed to determine if the optimal cutoff CSTB value can be applied to all ethnic groups and all underlying etiologies of liver disease.
In summary, although the accuracy of CSTB is equal to that of AFP, it has a higher sensitivity in differentiating HCC from nonmalignant chronic liver diseases than AFP. Therefore, CSTB or a combination of CSTB and AFP might be a potential marker for diagnosing HCC.
